Comprehensive Stock Comparison
Compare Pelthos Therapeutics Inc. (PTHS) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | PTHS | -318.4% net margin vs AGIO's -9.0% |
| Stability / Safety | PTHS | Beta 0.76 vs AGIO's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PTHS | +123.4% vs AGIO's -14.9% |
| Efficiency (ROA) | PTHS | -18.7% ROA vs AGIO's -29.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Pelthos Therapeutics is a biopharmaceutical company that develops and commercializes therapeutic products for patients with unmet medical needs. It generates revenue primarily from sales of its FDA-approved treatment ZELSUVMI for molluscum contagiosum — a viral skin infection — with additional potential from its proprietary NITRICIL nitric oxide technology platform. The company's competitive advantage lies in its first-mover position with the only FDA-approved prescription treatment for molluscum contagiosum, addressing a significant market gap.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PTHS leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
AGIO is the larger business by revenue, generating $45M annually — 6.0x PTHS's $7M. PTHS is the more profitable business, keeping -3.2% of every revenue dollar as net income compared to AGIO's -9.0%.
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $45M |
| EBITDAEarnings before interest/tax | -$21M | -$470M |
| Net IncomeAfter-tax profit | -$24M | -$401M |
| Free Cash FlowCash after capex | -$17M | -$414M |
| Gross MarginGross profit ÷ Revenue | +54.3% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -3.0% | -10.6% |
| Net MarginNet income ÷ Revenue | -3.2% | -9.0% |
| FCF MarginFCF ÷ Revenue | -2.3% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -7.7% | -111.0% |
Valuation Metrics
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $85M | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $87M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | -1.95x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9999.00x |
| Price / BookPrice ÷ Book value/share | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AGIO delivers a -31.2% return on equity — every $100 of shareholder capital generates $-31 in annual profit, vs $-40 for PTHS. On the Piotroski fundamental quality scale (0–9), PTHS scores 4/9 vs AGIO's 3/9, reflecting mixed financial health.
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -40.5% | -31.2% |
| ROA (TTM)Return on assets | -18.7% | -29.0% |
| ROICReturn on invested capital | — | -26.6% |
| ROCEReturn on capital employed | — | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | $2M | -$49M |
| Cash & Equiv.Liquid assets | $513,443 | $89M |
| Total DebtShort + long-term debt | $2M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -12.31x | — |
Total Returns (with DRIP)
A $10,000 investment in PTHS five years ago would be worth $22,339 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, PTHS leads with a +123.4% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors PTHS at 30.7% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -10.5% | +11.2% |
| 1-Year ReturnPast 12 months | +123.4% | -14.9% |
| 3-Year ReturnCumulative with dividends | +123.4% | +19.4% |
| 5-Year ReturnCumulative with dividends | +123.4% | -36.4% |
| 10-Year ReturnCumulative with dividends | +123.4% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +30.7% | +6.1% |
Risk & Volatility
PTHS is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs PTHS's 48.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 0.91x |
| 52-Week HighHighest price in past year | $54.29 | $46.00 |
| 52-Week LowLowest price in past year | $11.20 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +48.6% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 11K | 948K |
Analyst Outlook
| Metric | PTHSPelthos Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | — | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Pelthos Therapeutic… (PTHS) | $0.00 | $0.00 | — |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 2EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Pelthos Therapeutic… (PTHS) | -4.26 | -13.54 | -217.8% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 3Free Cash Flow — 5 Years
Pelthos Therapeutics Inc. generated $-6M FCF in 2024 (-270% vs 2022). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
PTHS vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is PTHS or AGIO a better buy right now?
Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PTHS or AGIO?
Over the past 5 years, Pelthos Therapeutics Inc. (PTHS) delivered a total return of +123.4%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in PTHS five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PTHS returned +123.4% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PTHS or AGIO?
By beta (market sensitivity over 5 years), Pelthos Therapeutics Inc. (PTHS) is the lower-risk stock at 0.76β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 20% more volatile than PTHS relative to the S&P 500.
04Which has better profit margins — PTHS or AGIO?
Pelthos Therapeutics Inc. (PTHS) is the more profitable company, earning -318.4% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps -318.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTHS leads at -300.5% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — PTHS or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is PTHS or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Pelthos Therapeutics Inc. (PTHS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.76), +123.4% 10Y return). Both have compounded well over 10 years (PTHS: +123.4%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between PTHS and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.